We are live on ! Find out more

AstraZeneca

AZN

Market cap $246B

158.73 USD

-1.39

0.87%

At close Updated Oct 8, 3:59 PM EDT

Pre-market

After hours

158.78

+0.05

0.03%

1 day

-0.87%

5 days

0.17%

1 month

-0.82%

3 months

-16.14%

6 months

-22.29%

Year to date

-13.33%

1 year

-7.04%

5 years

30.94%

10 years

147.55%

About: A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Employees: 96,100

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.4%

Neutral 41.7%

Negative 21.9%

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in prostate cancer patients.

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Proactive Investors

Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results

Jefferies maintained a 'buy' rating on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the biopharmaceutical company, with a 17,500p price target, representing 46% potential upside from its 11,958p share price. The broker expects AstraZeneca to report third-quarter revenue about 1% ahead of the Visible Alpha consensus and core earnings before interest and tax at 3% above expectations.

Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results

Zacks Investment Research

Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider

In the latest trading session, Astrazeneca (AZN) closed at $158.61, marking a +1.33% move from the previous day.

Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider

Proactive Investors

Citi raises AstraZeneca target to £186 as tozorakimab prospects improve

Citi raised its target price for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, to £186 from £178 and retained its 'buy' rating after recent clinical developments. The broker increased its peak sales forecast for tozorakimab to $7 billion and for SERENA-6 to $1.1 billion, more than offsetting the removal of its $1.7 billion forecast for SERENA-4.

Citi raises AstraZeneca target to £186 as tozorakimab prospects improve

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

AstraZeneca CEO Pascal Soriot told CNBC that Summit Therapeutics' lead drug could help power next-generation cancer combinations that could be the "future of cancer care." Soriot spoke exclusively with CNBC from the site of AstraZeneca's new more than $1 billion research and development facility in Kendall Square in Cambridge, Massachusetts.

AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment

AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 billion US ‌investment plan, a move expected to expand its workforce in the state by more than 50% in the coming years.

AstraZeneca to invest over $1 billion in Massachusetts, boost workforce

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company's existing presence in Cambridge and Boston and places its scientists at the heart of one of the world's most innovative life sciences ecosystems. Together with its site for genomic medicine at 100 Binney Street, The AstraZeneca R&D Center Kenda.

AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts

Zacks Investment Research

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

Summit is teaming up with AstraZeneca and Daiichi to test ivonescimab with Datroway across breast and lung cancers, broadening its potential.

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi.

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

See News Rankings

Price charts implemented using Lightweight Charts™